<DOC>
	<DOCNO>NCT03066648</DOCNO>
	<brief_summary>To characterize safety tolerability PDR001 and/or MBG453 combination decitabine relapsed/refractory AML patient , de novo AML patient candidate standard induction therapy , high risk MDS patient , identify recommended dos future study .</brief_summary>
	<brief_title>Study PDR001 and/or MBG453 Combination With Decitabine Patients With AML High Risk MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Written informed consent must obtain prior screen procedure 2 . Male female patient ≥ 18 year age present one following : Refractory/relapsed AML follow ≥1 prior therapy De novo AML patient candidate standard therapy High risk MDS 3 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 4 . Patient must candidate serial bone marrow aspirate and/or biopsy accord institution 's guideline willing undergo bone marrow aspirate and/or biopsy screening , end therapy study . Exceptions may consider documented discussion Novartis . 5 . Patients must fit standard treatment decitabine determine investigator per local decitabine package insert . Other inclusion criterion include protocol might apply . 1 . Patients receive prior decitabine hypomethylating agent treatment AML MDS . 2 . Patients active , know suspect autoimmune disease.Patients vitiligo , type I diabetes , residual hypothyroidism require hormone replacement , psoriasis require systemic treatment condition expect recur exclude . 3 . History , current druginduced interstitial lung disease pneumonitis grade ≥ 2 . 4 . Patients discontinue prior PD1 PDL1 direct therapy due treatment related toxicity include PDR001 contain arm study . Patients previously expose antiPD1/PDL1 treatment adequately treat skin rash replacement therapy endocrinopathies exclude . 5 . Treatment cytotoxic target antineoplastic within 3 week initiation study treatment . For patient received antibody immunotherapy , 4 week indicate washout period . Systemic antineoplastic therapy ( include cytotoxic chemotherapy , alphainterferon , kinase inhibitor target small molecule , toxinimmunoconjugates ) experimental therapy within 14 day 5 halflives , whichever short , first dose study treatment . 6 . Systemic chronic corticosteroid therapy ( ≥ 10 mg/day prednisone equivalent ) immunosuppressive therapy within 7 day first dose study treatment . Topical , inhale , nasal ophthalmic steroid allow . Other exclusion criterion include protocol might apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
</DOC>